Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RESP301
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : ConvaTec
Deal Size : $218.0 million
Deal Type : Divestment
Details : The divestment will allow 30 Technology to accelerate its ultra-broad spectrum NO-generation and rapidly advance its innovative and differentiated platform of NO-generating technologies, including RESP301, a NO-generating liquid designed to release NO in...
Brand Name : RESP301
Molecule Type : Small molecule
Upfront Cash : $55.9 million
April 19, 2023
Lead Product(s) : RESP301
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : ConvaTec
Deal Size : $218.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?
Reset All
